Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NSF Awards U.S. Genomics a $500K Phase II-B SBIR Grant

Published: Friday, October 07, 2005
Last Updated: Friday, October 07, 2005
Bookmark and Share
The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies.

U.S. Genomics, Inc. has announced that it has received a Phase II-B SBIR grant from the National Science Foundation.

The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies. 

U.S. Genomics plans to use this installment to develop its Substance Identification and Quantitation Using Molecular Barcodes (SIQUMB) technology.

“This additional SBIR award recognizes the achievements we've made in developing single molecule analysis and genomic mapping for commercialization,” said John J. Canepa, acting Chief Executive Officer of U.S. Genomics. 

“The ability to acquire and analyze molecular information has been made much more efficient with the invention of the SIQUMB molecular identification process.”

“This technology will be valuable for many commercial applications in life science research and in the healthcare industry.”

In July 2002, U.S. Genomics was awarded Phase I of the SBIR grant to create genomic maps by tagging and stretching individual DNA molecules.

During the Phase I project, U.S. Genomics achieved fundamental milestones by mapping long DNA molecules and substantially increasing the throughput and accuracy of the mapping technology.

In August 2003, the Company earned the subsequent Phase II grant.  As part of the Phase II application, researchers at U.S. Genomics enhanced the capabilities of the DNA mapping platform and invented SIQUMB.

The recent award will enable U.S. Genomics to continue its development and commercialization of the SIQUMB technology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. Genomics Announces Recipient of Outstanding Investigator in Single Molecule Biology Award
Dr. James A. Spudich will be presented the award at the 50th Annual Meeting of the Biophysical Society.
Tuesday, February 21, 2006
U.S. Genomics Announces New Chief Executive Officer
John J. Canepa has been promoted to President, CEO and member of the Board of Directors.
Friday, December 16, 2005
U.S. Genomics Expands its Efforts With New VP
U.S. Genomics Names Duncan Whitney as Vice President of Research and Development.
Friday, September 30, 2005
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!